The newest market entrant and possibly next autoimmune blockbuster has had an impressive launch so far, according to Spherix Global
Looking to the future, the approval of the first dual-therapy migraine label would make Nurtec a substantial competitive threat on
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked
With a plethora of agents in development, manufacturers who already have one leg in the dermatology biologic/small molecule space, such
Bolstering Tecfidera’s competitiveness with the glatiramer acetate class among treatment-naïve relapsing-remitting multiple sclerosis patients is Biogen’s best defense against anticipated
According to the latest quarterly update from Spherix Global Insights, strict protocols at large dialysis organizations (LDOs) are the leading
With Dupixent only capturing a piece of the potential candidate pie, there remains ample runway for new agents in development
According to a new report from Spherix Global Insights, provider reimbursement anxiety and escalating out-of-pocket costs, as patients live longer
Lack of access to Roche’s Ocrevus for primary progressive multiple sclerosis has stymied UK prescriber base growth and adoption over
Download Report Overview EXTON, Pa., Oct. 8, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by
Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer’s PF-0496582, AbbVie’s upadacitinib and Incyte’s topical ruxolitinib have
From: Multiple Sclerosis News Today By: Alice Melao
